Trial Profile
A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2013
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Etravirine (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- 05 Sep 2011 New trial record